Xavier Pivot is a French medical oncologist (MD), PhD in Pharmacology, Professor of University, and General Director of Paul Strauss Cancer Center and the Strasbourg Cancer Institute (ICANS).
Pr. X. Pivot’s focus lies in the research of anti-cancer drugs. Since the late 1990s, his main scientific interest has been centered on a therapeutic antibody, trastuzumab, and the HER2 (ERBB2)-positive breast cancer. He has worked on alternatives like lapatinib and on optimizing the use of trastuzumab, a subcutaneous form. He has researched improvement to biotherapies and in particular trastuzumab that would cut down on cost and allow more access to medications. The PHARE study illustrated this purpose as well as his involvement in the creation of trastuzumab biosimilars. Assessment of qualities and preservation of key quality attributes has been a main focus of his research and support his involvement in the development of anti HER2 targeted agents.